Tg Therapeutics Inc (TGTX) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Tg Therapeutics Inc   (NASDAQ: TGTX)


Tg Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Tg Therapeutics Inc's ROI in the second quarter of 2026?
Tg Therapeutics Inc achieved a return on average invested assets (ROI) of 39.51 % in its second quarter of 2026, this is above TGTX's average return on investment of -102.25%.
Tg Therapeutics Inc invested over the 12 months ending in its second quarter of 2026 $1,117 million

ROI decreased relative to the period ending Mar 31 2026, due to the decline in net income.

Within the Healthcare sector 31 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 86 to 91.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 130.02 % 112.56 % 87.52 % 84.16 % 78.55 %
Y / Y Net Income Change TTM 630.24 % 1079.81 % 1211.76 % 4059.06 % 778.88 %
Investment (TTM) in Millions 1,371 1,335 902 861 523
Return On Investment (TTM) 39.51 % 51.02 % 64.46 % 76.12 % 12.45 %
TGTX's Overall Ranking # 91 # 86 # 54 # 49 # 470
Seq. Investment Change TTM 23.41 % 30.5 % 18.01 % 21.02 % 14.04 %
Seq. Net Income Change TTM -4.42 % 3.29 % -0.07 % 640.14 % 54.43 %
Net Income (TTM) in Millions 441 462 447 447 60

TGTX Company Profile >> Back to TGTX Roi Comparisons >> See Annual TGTX Return On Investment



Return On Investment TGTX's Ranking
Within: No.
Industry # 17
Sector # 32
Overall # 91

Return On Investment Statistics
High Average Low
75.13 %
-102.25 %
-417.2 %
(Sep 30 2025)   (Mar 31 2020)







Financial Statements
Tg Therapeutics Inc's II. Quarter Investments $ 1,371 Millions TGTX's Balance sheet
Tg Therapeutics Inc's II. Quarter Income $ 8 Millions Quarterly TGTX's Income Statement
TGTX's Income by Division See TGTX's Income by Division


TGTX Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 902 479 276 130 304
Y / Y Investment Growth 88.46 % 73.59 % 112.16 % -57.28 % -47.5 %
Net Income in Millions 447 23 13 -198 -348
Y / Y Net Income Growth 1812.41 % 84.52 % - - -
Annual Return On Investment 49.55 % 4.88 % 4.59 % -152.53 % -114.36 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 49.55 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
TGTX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for TGTX's Competitors
Subscribers only: Roi for Tg Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for TGTX's Customers

Other Ratios
TGTX's Roa TGTX's Inventory Turnover Ratio TGTX's Growth Rates TGTX's Dividend Statistics
TGTX's Profitability Ratios TGTX's Asset Turnover Ratio TGTX's Dividend Growth
TGTX's Roe TGTX's Valuation Ratios TGTX's Financial Strength Ratios TGTX's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Interpace Biosciences Inc   100.71 %
Rigel Pharmaceuticals Inc  89.00 %
Oncotelic Therapeutics Inc   87.35 %
Arbutus Biopharma Corp  85.89 %
Actinium Pharmaceuticals Inc  84.38 %
Exelixis Inc   82.05 %
Lensar Inc   75.31 %
Ironwood Pharmaceuticals inc   70.54 %
Oramed Pharmaceuticals Inc  68.90 %
Indivior Pharmaceuticals Inc   68.79 %
Rallybio Corporation  68.28 %
Fortress Biotech Inc   68.27 %
Earth Science Tech Inc   64.38 %
Meiragtx Holdings Plc  55.83 %
Elite Pharmaceuticals Inc   53.48 %
Idexx Laboratories Inc  51.80 %
Aurinia Pharmaceuticals Inc   50.35 %
Qhslab Inc   48.94 %
Q32 Bio Inc   47.43 %
Vaxart Inc   46.17 %
Liquidia Corporation  42.09 %
Tg Therapeutics Inc   39.26 %
Medpace Holdings Inc   35.54 %
Mettler toledo International Inc   34.41 %
Eli Lilly And Company  33.95 %
Acadia Pharmaceuticals Inc   31.05 %
Caredx Inc   29.42 %
Adma Biologics Inc   28.94 %
Protalix Biotherapeutics inc   25.72 %
Pro dex Inc   24.29 %

Date modified: 2026-09-09T22:26:19+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.